if you take this medicine more than once a day, you may have to remember to take it at school or college. You or your mum, dad or carer will need to find out what the school rules are about this. The physician who elects to use methylphenidate for extended periods (over 12 months) should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the patient's condition (for children preferably during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued. Like all medicines, methylphenidate can cause side effects, although not everyone gets them. Common side effects Each modified-release capsule hard contains 10 mg methylphenidate hydrochloride, equivalent to 8.65 mg methylphenidate.

Treatment must be stopped if the symptoms do not improve after appropriate dosage adjustment over a one-month period. If paradoxical aggravation of symptoms or other serious adverse events occur, the dosage should be reduced or discontinued. If you forget doses often, it may help to set an alarm to remind you. You could also ask your pharmacist for advice on other ways to help you remember to take your medicine. What if I take too much? Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy. Aqua, Sodium Laureth Sulfate, Sodium Chloride, Cocamidopropyl Betaine, Cocamide DEA, Glycol Distearate, Cocamide MEA, Laureth-10, Piroctone Olamine, Glycerin, Parfum, Citric Acid monohydrate, Methylchloroisothiazolinone, Methylisothiazolinone, Benzyl Alcohol, Sodium Shale Oil Sulfonate (Ichthyol Pale). BaleníThe patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. If the signs and symptoms are not too severe and the patient is conscious, gastric contents may be evacuated by induction of vomiting or gastric lavage. Before performing gastric lavage, control agitation and seizures if present and protect the airway. Other measures to detoxify the gut include administration of activated charcoal and a cathartic. In the presence of severe intoxication, a carefully titrated dose of a benzodiazepine may be given before performing gastric lavage. There are several brands of ‘slow-release’ methylphenidate tablets or capsules (they may also be referred to as ‘modified-release’ or ‘XL’). These release some of the methylphenidate straight away but release the rest slowly throughout the day. For this reason, they can be taken less often.

The medicine helps with your brain activity. It can help improve your attention, help you concentrate, and make you less impulsive. Do not take methylphenidate if you are trying to get pregnant and use a good method of contraception while taking the drug. This medicine has been prescribed for you or your child. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

Patients who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden cardiac or unexplained death or malignant arrhythmia) and physical exam to assess for the presence of cardiac disease and should receive further specialist cardiac evaluation if initial findings suggest such history or disease. Patients who develop symptoms such as palpitations, exceptional chest pain, unexplained syncope, dyspnoea, or other symptoms suggestive of cardiac disease during methylphenidate treatment should undergo a prompt specialist cardiac evaluation. If you forget a dose, skip the missed dose and wait until it’s time for the next dose. Take the next dose as usual. Each modified-release capsule, hard contains 20 mg methylphenidate hydrochloride equivalent to 17.30 mg methylphenidate. If you or your child is taking other medicines, methylphenidate may affect how well they work or may cause side effects. Tell your doctor if you or your child is taking medicines to treat: Each modified-release capsule hard contains 5 mg methylphenidate hydrochloride, equivalent to 4.35 mg methylphenidate.

The usual starting dose for adults is 18mg, taken once in the morning. Your doctor may gradually increase the dose by 18mg at a time (usually weekly) until they find the dose that works best or you. How to take it How to take standard tablets or capsules The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. Methylphenidate treatment can usually be discontinued during or after puberty, when used in children with ADHD. The physician who elects to use methylphenidate for extended periods (over 12 months) should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the patient's condition (for children preferably during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued. Do not take methylphenidate if you have taken a monoamine oxidase inhibitor antidepressant (MAOI) like moclobemide, phenelzine, isocarboxazid or tranylcypromine in the last 14 days. Methylphenidate treatment is not indicated in all children with ADHD and the decision to use the medicinal product musMethylphenidate should be used with caution in patients with epilepsy. Methylphenidate may lower the convulsive threshold in patient with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and rarely in patients without a history of convulsions and no EEG abnormalities. If seizure frequency increases or new-onset seizures occur, methylphenidate should be discontinued. Taking methylphenidate with these medicines can cause a sudden increase in your blood pressure. This could be dangerous. MAOIs include: Modified-release tablets: 18mg, 27mg, 36mg and 54mg strengths (Delmosmart, Matoride XL, Xaggitin XL, Xenidate XL and Concerta XL) Methylphenidate is associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette's syndrome has also been reported. Family history should be assessed and clinical evaluation for tics or Tourette's syndrome should precede use of methylphenidate. Patients should be regularly monitored for the emergence or worsening of tics during treatment with methylphenidate. Monitoring should be at every adjustment of dose and then at least every 6 months or every visit. These common side effects may happen in more than 1 in 100 people. Keep taking the medicine, but tell your doctor if they bother you or do not go away:

Each modified-release capsule, hard contains 30 mg methylphenidate hydrochloride equivalent to 25.95 mg methylphenidate. If the effect of the medicinal product wears off too early in the evening, disturbed behaviour may recur. Very common side effects of taking methylphenidate (affecting more than one in ten people) include: a sudden increase in body temperature, very high blood pressure and severe convulsions (‘Neuroleptic Malignant Syndrome’). It is not certain whether this side effect is caused by methylphenidate or other drugs that may be taken in combination with methylphenidate The pros and cons of a small evening dose of immediate-release methylphenidate versus disturbances in falling asleep should be considered.

your doctor will increase your dose in increments of 10 mg daily, depending on how well you tolerate the medicine and how effective it is For some high-risk substance abuse patients, methylphenidate or other stimulants may not be suitable and non-stimulant treatment should be considered. Caution is recommended when administering methylphenidate with dopaminergic active substances, including antipsychotics. Because a predominant action of methylphenidate is to increase extracellular dopamine levels, methylphenidate may be associated with pharmacodynamic interactions when co-administered with direct and indirect dopamine agonists (including DOPA and tricyclic antidepressants) or with dopamine antagonists including antipsychotics.